Marker Therapeutics, Inc. MRKR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Marker Therapeutics, Inc. reported revenue across 8 products and services; the largest, Grant, was $3.55M (-46.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Grant$3.55Mshare n/a-46.2% yoy
- Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia$900Kshare n/a-79.6% yoy
- National Institutes Of Health Small Business Innovation Research For Lymphoma Grant$665Kshare n/a0.0% yoy
- Cprit Pancreatic Grant$574Kshare n/ano prior
- National Institutes Of Health Small Business Innovation Research$472Kshare n/a-51.9% yoy
- National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer$426Kshare n/a+5831.0% yoy
- National Institutes Of Health National Cancer Institute Grant$391Kshare n/a+6621.1% yoy
- Fda Grant$118Kshare n/a-77.2% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Cprit Pancreatic Grant$252K33.5%+1906.2% yoy
- Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia$209K27.7%-4.2% yoy
- National Institutes Of Health Small Business Innovation Research$117K15.5%+20.4% yoy
- National Institutes Of Health National Cancer Institute Grant$98.6K13.1%+593.8% yoy
- National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer$73.5K9.8%+820.9% yoy
- Fda Grant$2.9K0.4%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.